Neocip M

Ciprofloxacin:

• Pharmacological action
• Pharmacokinetics
• Why is Neocip M prescribed?
• Dosage and administration
• Neocip M (Ciprofloxacin) side effects, adverse reactions
• Contraindications
• Neocip M (Ciprofloxacin) Cipla: restrictions to using
• Using during pregnancy and breastfeeding
• Special instructions
• Precautionary measures
• Neocip M (Ciprofloxacin) drug interactions
• Neocip M in case of emergency / overdose
• Neocip M (Ciprofloxacin) reviews

Pharmacological action

Neocip M is a broad-spectrum antimicrobial drug of fluoroquinolone group with bactericidal action. Inhibits DNA gyrase and inhibits the synthesis of bacterial DNA. Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

Neocip M (Ciprofloxacin) is active against Staphylococcus spp. (including strains producing and not producing penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Neocip M (Ciprofloxacin) is active against bacteria producing beta-lactamases.

Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides resistant to Neocip M (Ciprofloxacin). The effect on Treponema pallidum is studied not enough.

Pharmacokinetics

Neocip M (Ciprofloxacin) rapidly absorbed from the gastrointestinal tract. Bioavailability after oral administration of 70%. Eating has a little effect on the absorption of Neocip M (Ciprofloxacin). Plasma protein binding is 20-40%. Distributed in tissues and body fluids. It penetrates the cerebrospinal fluid: the concentration of Neocip M (Ciprofloxacin) for not inflamed meninges reach 10% with inflammation - up to 37%. High concentrations are achieved in bile. Excreted in the urine and bile.

Why is Neocip M prescribed?

Infectious-inflammatory diseases caused by microorganisms susceptible to Neocip M (Ciprofloxacin), including respiratory diseases, diseases of abdominal and pelvic organs, bones, joints, skin, septicemia; severe infections of ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity.

For Neocip M (Ciprofloxacin) local use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meybomity. Infectious lesions in the eyes from injury or contact with foreign bodies. Preoperative prophylaxis in ophthalmic surgery.

Dosage and administration

Individual. For oral administration dose of Neocip M is 250-750 mg 2 times / day. Treatment duration is from 7-10 days to 4 weeks.

For IV administration a single dose is 200-400 mg, the multiplicity of the introduction is 2 times / day, duration of treatment - 1-2 weeks and more if necessary. May be IV injected as jet but more preferably a drip for 30 minutes.

When Neocip M (Ciprofloxacin) applied topically instilled 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After improving the intervals between instillation can be increased. The maximum oral daily dose for adults is 1.5 g.

Neocip M (Ciprofloxacin) side effects, adverse reactions

Digestive system: nausea, vomiting, diarrhea, abdominal pain, increase in liver transaminases, alkaline phosphatase, LDH, bilirubin, pseudomembranous colitis.

CNS: headache, dizziness, fatigue, insomnia, nightmares, hallucinations, fainting, disorders of vision.

Urinary system: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase of serum creatinine.

Hemopoietic system: eosinophilia, leukopenia, neutropenia, changes in the number of platelets.

Cardiovascular system: tachycardia, cardiac arrhythmias, hypotension.

Allergic reactions: itching, urticaria, Quincke's edema, Stevens-Johnson syndrome, arthralgia.

Adverse reactions associated with the chemotherapeutic effect: candidiasis.

Local reactions: pain, phlebitis (for IV injections). When applying eye drops in some cases may be mild pain and conjunctival hyperemia.

Other: vasculitis.

Contraindications

Pregnancy, lactation, childhood and adolescence to 15 years, increased sensitivity to Neocip M (Ciprofloxacin) and other drugs hinolonovogo series; deficiency of glucose-6-phosphate dehydrogenase; in ophthalmology: viral keratitis.

Neocip M (Ciprofloxacin) Cipla: restrictions to using

Pronounced cerebral arteriosclerosis, cerebral circulatory disorder, mental illness, epilepsy, epileptic syndrome, marked renal and / or hepatic insufficiency.

Using during pregnancy and breastfeeding

Contraindicated in pregnancy ; Neocip M (Ciprofloxacin) crosses the placenta, excreted in breast milk.

In experimental studies found that it causes arthropathy. In experiments on rats and mice treated with Neocip M (Ciprofloxacin) in doses exceeding the usual daily dose for a person 6 times, adverse effects on the fetus is not revealed. In experiments on rabbits treated with oral dose of Neocip M (Ciprofloxacin) 30 and 100 mg / kg, it is shown that the drug causes disruption of the gastrointestinal tract, leading to loss of body weight in females and increase the number of miscarriages but teratogenicity not found. When IV introduction to the doses of 20 mg / kg Neocip M (Ciprofloxacin) did not exert toxic effects on the mother and embryo, showed no teratogenicity. The use of local forms of Neocip M (Ciprofloxacin) in pregnancy is possible if the anticipated benefits exceed the potential risk to the fetus.

Category of the fetus by FDA - C.

Neocip M (Ciprofloxacin) is excreted in breast milk, so the period of lactation should decide, stop taking Neocip M (Ciprofloxacin) or breastfeeding based on the degree of importance of the use of drugs for the mother.

With careful use of local forms of Neocip M (Ciprofloxacin) in breast-feeding (not known whether Neocip M (Ciprofloxacin) is excreted in breast milk when applied topically).

Special instructions

Patients with impaired renal function requires correction dosing regimen. With caution used in elderly patients, with cerebral arteriosclerosis, cerebral circulatory disorders, epilepsy, convulsive syndrome of unknown etiology.

During treatment patients with Neocip M (Ciprofloxacin) should receive enough amounts of liquids.

In the case of persistent diarrhea Neocip M (Ciprofloxacin) should not be taken.

At the same time of Neocip M (Ciprofloxacin) IV introduction and barbiturates is necessary to monitor heart rate, blood pressure, ECG. In the course of treatment is necessary to monitor blood concentrations of urea, creatinine, hepatic transaminases.

In the period of treatment may decrease the reactivity (especially when used with alcohol).

Not allowed the introduction of Neocip M (Ciprofloxacin) subconjunctival or directly into the anterior chamber of the eye.

Precautionary measures

Due to the threat of adverse reactions from the CNS Neocip M should be used only according to the life in the pathology of the CNS in history: organic brain lesions, epilepsy, lowering the convulsive threshold, severe atherosclerosis of the brain (risk of circulatory disorders, stroke), the elderly, with severely impaired renal function and liver (requires monitoring concentrations in blood plasma).

Patients with allergic reactions to fluoroquinolone derivatives in history may develop reactions to Neocip M (Ciprofloxacin). During the period of treatment should avoid sunlight and UV radiation, intense physical exercise, control of drinking mode, pH of urine.

Reported cases of crystalluria, particularly in patients with alkaline reaction of urine (pH 7 or more). In order to avoid the development of crystalluria unacceptable excess of the recommended daily dose, should also be adequate fluid intake and maintaining acidic urine.

If you have pain in the tendons or the first signs tendovaginitah treatment should be discontinued (described isolated cases of inflammation or tendon rupture during fluoroquinolone treatment).

It can reduce the speed of psychomotor reactions, especially against the backdrop of alcohol, that should be considered for patients who work with potentially dangerous machinery or drive vehicles.

If you have severe diarrhea, pseudomembranous colitis should be excluded (for which Neocip M (Ciprofloxacin) is contraindicated). At the same time of barbiturates IV injections requires monitoring function of the cardiovascular system (heart rate, BP, ECG). Teenagers under 18 years shall be appointed only if the pathogen resistance to other chemotherapeutic drugs. The solution in the form of eye drops are not designed for intraocular injections. The use of other ophthalmic means the interval between injections should be at least 5 minutes.

Neocip M (Ciprofloxacin) drug interactions

Activity increases when combined with beta-lactam antibiotics, aminoglycosides, vancomycin, clindamycin, metronidazole. Sukralfat, bismuth preparations, antacids containing aluminum ions, magnesium or calcium, cimetidine, ranitidine, vitamin and mineral supplement, iron sulfate, zinc, didanosine (recommended for 2 hours before or 4 hours after these drugs) reduce the suction. Probenecid, azlocillin increase the concentration in the blood. Decreases clearance and increases in plasma caffeine, aminophylline and theophylline (increased likelihood of side effects). Neocip M (Ciprofloxacin) enhances the effect of warfarin and other oral anticoagulants (prolongs bleeding time). Increases nephrotoxicity of cyclosporine, increase the risk of CNS excitability and convulsive reactions against the background of NSAIDs. Medicines alkalinizing the urine (citrates, sodium bicarbonate, carbonic anhydrase inhibitors) reduce the solubility (increases the probability of crystalluria). Infusion solutions of Neocip M (Ciprofloxacin) ready to use can be combined with infusion solutions: 0.9% sodium chloride solution, Ringer's solution, Ringer lactate, 5 and 10% dextrose, 10% solution of fructose, and a solution containing 5% dextrose with 0,225 or 0.45% sodium chloride. Incompatible with solutions having a pH > 7.

Neocip M in case of emergency / overdose

May occur after receiving a single large dose or prolonged use. If a single dose of less than 150 mg / kg, acute poisoning feel light, 150-300 mg / kg - moderate, when using higher doses - heavy.

Symptoms: No specific symptoms.

Treatment: gastric lavage, the use of emetic drugs, the introduction of large quantities of liquid, the creation of acidic urine, in addition - hemodialysis and peritoneal dialysis (can be derived only 10% of the drug), all events are held on the background to maintain vital functions. The specific antidote is unknown.

Metronidazole:

• Pharmacological action
• Pharmacokinetics
• Why is Neocip M prescribed?
• Dosage and administration
• Neocip M (Metronidazole) side effects, adverse reactions
• Neocip M contraindications
• Using during pregnancy and breastfeeding
• Special instructions
• Neocip M drug interactions
• Neocip M in case of emergency / overdose
• Neocip M (Metronidazole) reviews

Pharmacological action

Neocip M is an anti protozoal agent. It is believed that the mechanism of action is associated with DNA damage-sensitive microorganisms. Active against Trichomonas vaginalis, Gardnerella vaginalis, Giardia lamblia, Entamoeba histolytica, and obligate anaerobic bacteria (including Bacteroides spp., Fusobacterium spp.).

Aerobic bacteria are resistant to Neocip M (Metronidazole).

In combination with amoxicillin Neocip M (Metronidazole) is active against Helicobacter pylori. It is believed that amoxicillin inhibits the development of resistance of Helicobacter pylori to Neocip M (Metronidazole).

Pharmacokinetics

Neocip M (Metronidazole) well absorbed after oral administration. The bioavailability is 80%. Neocip M (Metronidazole) is distributed in tissues and body fluids. This medication crosses the placental barrier and the BBB. Binding to plasma proteins is 20%. Neocip M (Metronidazole) is metabolized in the liver by oxidation and binding to glucuronic acid. T_1/2 is 8 hours. This drug is excreted in the urine (60-80%) and feces (6-15%).

Why is Neocip M prescribed?

Trichomonazice vaginitis and urethritis in women, trichomonazice urethritis in men, giardiasis, amoebic dysentery, anaerobic infections caused by metronidazole-sensitive organisms, combination therapy of severe mixed aerobic-anaerobic infections. Preventing anaerobic infection in surgery (particularly abdominal, urinary tract). Chronic alcoholism.

Neocip M (Metronidazole) in combination with amoxicillin: chronic gastritis in acute phase, gastric ulcer and duodenal ulcer in acute phase, associated with Helicobacter pylori.

For external and topical use: treatment of acne vulgaris and pink, bacterial vaginosis, treatment of long-term healing of wounds and trophic ulcers.

Dosage and administration

Neocip M is administered for oral use for adults and children over 12 years in 7.5 mg / kg every 6 h or 250-750 mg 3-4 times / day. For children up to 12 years the dose is 5-16.7 mg / kg 3 times / day. For IV injections for adults and children over 12 years starting dose is 15 mg / kg, followed by 7.5 mg / kg every 6 hours or depending on the etiology of the disease - by 500-750 mg every 8 hours. The duration of treatment and frequency of tests is determined individually.

Intravaginally - 500 mg 1 time a night.

In combination with amoxicillin (2.25 g / day) daily dose of Neocip M (Metronidazole) is 1.5 g; multiplicity of admission - 3 times / day. For patients with severe renal impairment (creatinine clearance less than 30 ml / min) and / or liver daily dose of Neocip M (Metronidazole) is 1 g (amoxicillin - 1.5 g / day), the multiplicity of the reception is 2 times / day. This medication takes for external and local use 2 times / day, doses are determined individually.

The maximum daily dose for adults when taken orally and IV is 4 g.

Neocip M (Metronidazole) side effects, adverse reactions

Digestive system: nausea, vomiting, anorexia, metallic taste in the mouth.

CNS and peripheral nervous system: headache, nervousness, irritability, insomnia, dizziness, ataxia, weakness, confusion, depression, peripheral neuropathy, seizures, hallucinations.

Allergic reactions: skin rash, itching, hives.

Hemopoietic system: leucopenia.

Local reactions: irritation.

Other: arthralgia, burning sensation in the urethra.

Neocip M contraindications

Organic CNS lesions, blood diseases, liver problems, I trimester of pregnancy, hypersensitivity to Neocip M (Metronidazole).

Using during pregnancy and breastfeeding

Neocip M is rapidly crosses the placental barrier. In II and III trimester of pregnancy Neocip M (Metronidazole) is used only for health reasons.

Neocip M (Metronidazole) is excreted in breast milk. If necessary, use during lactation should solve the issue of termination of breastfeeding.

Special instructions

Patients should with careful use of Neocip M (Metronidazole) in liver diseases.

In combination with amoxicillin this medication is not recommended for patients younger than 18 years. During the treatment period it is necessary the regular control of pattern of peripheral blood.

During the treatment of Trichomonas vaginitis in women and Trichomonas urethritis in men patients should refrain from sexual activity, simultaneous treatment of both partners is mandatory.

During the taking of Neocip M (Metronidazole) there is a more dark staining of urine.

During treatment with Neocip M (Metronidazole) should avoid alcohol because to violations of the oxidation of alcohol can accumulate acetaldehyde. As a result may develop reactions similar to those characteristic of disulfiram (abdominal cramps, nausea, vomiting, headache, a sudden rush of blood to the face).

Neocip M drug interactions

Simultaneous administration of Neocip M (Metronidazole) with: